Exclusive! TOXIC STUFF inside New Self-Amplifying sa-mRNA MONSTROUS Covid VACCINES Authorized by EU. Patent unveils same Pfizer’s Carcinogen Biochemicals Elements
by Fabio Giuseppe Carlo Carisio
The controversy over self-replicating vaccines had erupted ever since Japan decided to authorize their use, without particular constraints on a temporary emergency trial, in December 2023.
The scientific community, alarmed by the many critical issues regarding the efficacy and safety of the new biotechnology of mRNA genetic serums, had split between doctors and bioimmunologists who began to consider them “monstrous” and those who acclaimed their arrival as a sensational pharmacological innovation for the well-known global immunization project launched by Bill Gates in Italy together with the Rockefeller Foundation.
«Japan is leading the way in the approval of a new generation of vaccines with a completely new mechanism of action, which could become a weapon against many diseases, including tumors, and which requires lower doses, therefore with fewer side effects. The peculiarity of the new vaccines is in their ability to self-replicate and for this reason they are indicated with the acronym ‘sa-mRna’, from the English ‘self-amplifying mRna'” wrote the Italian news agency ANSA at the time.
Last February 11, the European Commission, chaired by Ursula Von der Leyen, after the opinion of the European Medicine Agency (EMA), also gave the green light to the use in the European Union of one of them: the Kostaive-Zaporeman produced by the Dutch company Arcturus Therapeutics Europe B.V. despite the unknowns.
And despite the patent, published almost simultaneously with the authorization and reported by us here exclusively, confirms that it contains some of the most dangerous and carcinogenic substances already present in the previous mRNA gene serums of Pfizer-Biontech….
The New Gene Therapy sa-mRNA with Self-Replicating Genes
This new type of “gene therapies” are similar to the Covid-19 messenger RNA ones. Both are based on the messenger RNA molecule, the right arm of DNA that transfers the information contained in the genome to the structures of the cells responsible for the production of proteins.
However, it would be a mistake to consider them relatives: due to their particular mechanism of action, sa-mRNA vaccines “are profoundly different from mRNA ones”, observes Anna Blakney, a bioengineer at the Canadian University of British Columbia, on the Nature website. This is why, compared to the former, they require much smaller doses, equal to one sixth.
The fundamental difference is in the mechanism of operation: mRNA vaccines exploit the structures found in cells, giving them the information necessary to produce specific antibodies against a particular virus; sa-mRNA vaccines do not perform this step because they have genes that allow them to self-replicate, that is, to directly produce antibodies in cells autonomously and in greater quantities.
The Unknown on Carcinogenic DNA Fragments
But here the disturbing unknowns arise.
Even the study conducted by an American university laboratory funded by the FDA (Food and Drug Administration, the regulatory body for drugs in the USA) recently reported the release of DNA fragments in human blood cells and organs in such a concentration as to be considered potentially carcinogenic, as already reported by multiple studies by authoritative experts in bioimmunology and genomics and also by the surgeon general of Florida Joseph A. Ladapo who asked for its withdrawal.
Just as 9 US states have started legal action to ban mRNA Covid serums, as has already happened in some places in Australia, here comes the EU launching these new products on the market that contain an even greater potential for DNA alteration due to their ability to self-replicate…
«Kostaive will be available as a powder for dispersion for injection. Kostaive is a RNA-based COVID-19 vaccine (ATC code: J07BN01). It contains a self-amplifying mRNA that encodes the SARS-CoV-2 spike protein. Self-amplifying means that the mRNA also carries instructions to make a protein called replicase. Once administered into a muscle, the replicase protein makes more copies of the mRNA, which the cell can use to make more spike protein. Vaccination with Kostaive induces the production of neutralising antibodies and a cellular immune response targeting the spike protein, which helps protect people against COVID-19».
This wrote the European Medicine Agency (EMA) in its positive opinion of 12 December 2024 (link among sources)«The benefit of Kostaive as a primary vaccination against COVID-19 was shown in a large study in which adults received either two doses of Kostaive or placebo. Compared with placebo, vaccination with Kostaive led to a reduction in the proportion of patients who developed symptomatic COVID-19 between one week and 3 months after the second vaccine dose. A smaller immunobridging study also showed that Kostaive is effective as a heterologous booster vaccination (when the primary vaccination was made with another COVID-19 vaccine). The most common side effects with Kostaive are injection-site reactions (pain and tenderness), arthralgia, myalgia, headache, dizziness, fatigue, chills and pyrexia»
EMA adds without providing data on clinical trials and any genotoxicity and carcinogenicity studies that were never done for previous mRNA vaccines.
Arcturus CEO: “More Long-Lasting Protection Than mRNA Vaccines”
«Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved».
It can be read on the company’s official website.
«Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries)».
“KOSTAIVE and sa-mRNA technology signify a major advancement in vaccine innovation, providing the potential for broader and more enduring protection,” said Joseph Payne, CEO of Arcturus. “This approval highlights the clinical promise of KOSTAIVE and its ability to protect against the ever-changing COVID-19 virus.”
«A follow-up analysis evaluating a booster dose of KOSTAIVE also showed that the vaccine elicited superior immunogenicity and antibody persistencefor up to 12 months postvaccination against multiple SARS-CoV-2 strains in both younger and older adult age groups versus the same mRNA comparator»
adds the company which, however, just like EMA, does not publish studies on the safety and genotoxicity of this new genetic therapy.
The Toxic Substances Revealed by the Patent we Publish in Preview
«Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses».
It is written in the patent published on Justia registered on June 30, 2023 with the number US 12220455 (link among the sources).
«The present disclosure relates generally to inducing immune responses against infectious agents and tumor antigens and more specifically to self-transcribing and replicating RNA for antigen expression».
Lipid Nanoparticles
We have seen that Moderna has also already developed a gene serum against cancer already tested in a doctor affected by a form of turbo-cancer probably related to his previous inoculations of Covid vaccines.
«In yet another aspect, the disclosure provides a composition comprising any of the nucleic acid molecules provided herein. In some embodiments, the composition further comprises a lipid. In some embodiments, the lipid comprises an ionizable cationic lipid. In some embodiments, the ionizable cationic lipid has a structure of or a pharmaceutically acceptable salt thereof.In yet another aspect, the disclosure provides a composition comprising any of the nucleic acid molecules described herein and a lipid formulation. In some embodiments, the lipid formulation is selected from a lipoplex, a liposome, a lipid nanoparticle, a polymer-based carrier, an exosome, a lamellar body, a micelle, and an emulsion (pg. 8 of the Patent)».
This is what the Arcturus patent highlights, referring to the lipid nanoparticles whose potential toxicity was revealed by the Italian biochemist Gabriele Segalla in three different studies published internationally, later confirmed even by the same doctors who created the mRNA Moderna genetic serum.
Frankenstein’s Diabolic Molecule
«In some embodiments, the nucleotide reduced is uridine. For example, the present disclosure provides nucleic acids with altered uracil content wherein at least one codon in the wild-type sequence has been replaced with an alternative codon to generate a uracil-altered sequence».
Given the complexity, we will not delve into the analysis of the typologies but will limit ourselves to a mere list to refer to previous investigations…
«Examples of pseudouridines include N1-methylpseudouridine (also referred to herein as “N1MPU”), N1-ethylpseudouridine, N1-propylpseudouridine, N1-cyclopropylpseudouridine, N1-phenylpseudouridine, N1-aminomethylpseudouridine, N3-methylpseudouridine, N1-hydroxypseudouridine, and N1-hydroxymethylpseudouridine. Examples of nucleic acid monomers include modified and chemically-modified nucleotides, including any such nucleotides known in the art (pages 22-27 in the Patent».
The most attentive readers of Gospa News will remember that N1-methylpseudouridine (m1Ψ), which we call the diabolical Frankenstein molecule due to its multiple manipulations, has been indicated by various studies as potentially carcinogenic:
«Evidence is provided that adding 100 % of N1-methyl-pseudouridine (m1Ψ) to the mRNA vaccine in a melanoma model stimulated cancer growth and metastasis, while non-modified mRNA vaccines induced opposite results, thus suggesting that COVID-19 mRNA vaccines could aid cancer development».
This was reported reported in the Abstract of the study by Rubio-Casillas et al. published after careful review by the prestigious journal Science Direct.
«The utilization of mRNA vaccines in the context of infectious disease has no precedent. The many alterations in the vaccine mRNA hide the mRNA from cellular defenses and promote a longer biological half-life and high production of spike protein» wrote in a study biophysicist Stephanie Seneff of the prestigious MIT (Massachusetts Institute of Technology) warning of the dangers of interaction arising from a consequent «dysregulation of the G4-RNA-protein binding system and a wide range of potential disease-associated cellular pathologies including suppression of innate immunity, neurodegeneration, and malignant transformation».
«In COVID-19 mRNA vaccines, natural uracil bases are replaced with modified pseudouracil. This study investigates the potential consequences of this modification on protein synthesis. Occasionally, ribosomes may overlook these modified bases, leading to a shift in the reading frame of the genetic code. We examine the spike protein in the context of these shifted reading frames and identify the resulting proteins. Our analysis focuses on the potential formation of prion-like or amyloidogenic proteins due to this frame-shifting process»
This wrote the biomathematician Jean-Claude Perez, continuing a study started with the late biologist Luc Montagnier, managed to identify that some of those anomalous proteins.
The SV40 Carcinogenic Promoter
But the potential risks don’t end there…
«In some aspects, DNA molecules provided herein include a promoter for in vivotranscription. Generally, the promoter for in vivo transcription is an RNA polymerase II (RNApol II) promoter. Any RNA pol II promoter can be included in DNA molecules provided herein, including constitutive promoters, inducible promoters, and tissue-specific promoters. Exemplary constitutive promoters include a cytomegalovirus (CMV) promoter, an EF1α promoter, an SV40 promoter, a PGK1 promoter, a Ubc promoter, a human beta actin promoter, a CAG promoter, and other (page 41 in the Patent)».
The SV40 promoter is the one that Pfizer-Biontech tried to hide from the European Medicines Agency because it was also considered potentially carcinogenic.
But it was revealed by the research of American and Canadian genomics and bioimmunology experts…
We thank Ursula Von der Leyen, President of the European Commission, and the Italian Commissioner Raffaele Fitto, for having approved this new vaccine experimentation with partly very dangerous and partly unknown effects in order to support the transhumanist policies of the Italian Minister of Health Orazio Schillaci, of Big Pharma and of the global immunization project started with the SARS-Cov-2 Pandemic built in a laboratory.
Fabio Giuseppe Carlo Carisio
director of Gospa News
investigative journalist since 1991
VT columnist since 2019
© COPYRIGHT GOSPA NEWS
reproduction prohibited without authorization
follow Fabio G.C. Carisio on Twitter
and Gospa News on Telegram
MAIN SOURCES
EUROPEAN MEDICINES AGENCY ON KOSTAIVE ANTI-COVID VACCINE
JUSTIA – PATENT ARCTURUS – Coronavirus vaccine compositions and methods
GOSPA NEWS – BIG PHARMA & VACCINES
RELATED TOPICS
Kentucky Becomes the 9th U.S. State with Legislative Efforts to BAN mRNA Injections
